» Articles » PMID: 37634218

Immunological Risk and Complement Genetic Evaluations in Early Onset De Novo Thrombotic Microangiopathy After Living Donor Kidney Transplantation: A Japanese Multicenter Registry

Abstract

Background: Thrombotic microangiopathy (TMA) after kidney transplantation (KTx), particularly early onset de novo (dn) TMA, requires immediate interventions to prevent irreversible organ damage. This multicenter study was performed to investigate the allogeneic clinical factors and complement genetic background of dnTMA after KTx.

Methods: Perioperative dnTMA after KTx within 1 week after KTx were diagnosed based on pathological or/and hematological criteria at each center, and their immunological backgrounds were researched. Twelve aHUS-related gene variants were examined in dnTMA cases.

Results: Seventeen recipients (15 donors) were enrolled, and all dnTMA cases were onset within 72-h of KTx, and 16 of 17 cases were ABO incompatible. The implementation rate of pre-transplant plasmaphereses therapies were low, including cases with high titers of anti-A/anti-B antibodies. Examination of aHUS-related gene variants revealed some deletions and variants with minor allele frequency (MAF) in Japan or East Asian genome databases in genes encoding alternative pathways and complement regulatory factors. These variants was positive in 8 cases, 6 of which were positive in both recipient and donor, but only in one graft loss case.

Conclusions: Although some immunological risks were found for dnTMA after KTx, only a few cases developed into TMA. The characteristic variations revealed in the present study may be novel candidates related to dnTMA in Japanese or Asian patients, but not pathogenic variants of aHUS. Future studies on genetic and antigenic factors are needed to identify factors contributing to dnTMA after KTx.

References
1.
Goodship T, Cook H, Fakhouri F, Fervenza F, Fremeaux-Bacchi V, Kavanagh D . Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016; 91(3):539-551. DOI: 10.1016/j.kint.2016.10.005. View

2.
Garg N, Rennke H, Pavlakis M, Zandi-Nejad K . De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev (Orlando). 2017; 32(1):58-68. DOI: 10.1016/j.trre.2017.10.001. View

3.
Gonzalez Suarez M, Thongprayoon C, Mao M, Leeaphorn N, Bathini T, Cheungpasitporn W . Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(7). PMC: 6679118. DOI: 10.3390/jcm8070919. View

4.
Noris M, Remuzzi G . Atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 361(17):1676-87. DOI: 10.1056/NEJMra0902814. View

5.
Satoh S, Saito K, Harada H, Okumi M, Saito M . Survey of thrombotic microangiopathy within 1 week after kidney transplantation between 2010 and 2015 in Japan. Clin Exp Nephrol. 2018; 23(4):571-572. DOI: 10.1007/s10157-018-1655-2. View